Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
SoftBank Group has launched a joint venture with Tempus AI, named SB TEMPUS, to analyze personal medical data using artificial intelligence, aiming to develop personalized treatment recommendations. This initiative marks a significant step in integrating AI into healthcare in Japan. SoftBank founder Masayoshi Son outlined these plans during a rare public appearance, highlighting the company's $200 million investment in Tempus AI ahead of its IPO on Nasdaq. Additionally, SoftBank's Vision Fund 2 is investing between $10 million and $20 million in AI search startup Perplexity, which is now valued at $3 billion. This investment is part of SoftBank's broader strategy to back innovative AI technologies.
Scoop: Masayoshi Son's Softbank is making its next bet on AI, investing as much as $20 million in Perplexity. It's part of a larger funding round that triples the startup’s valuation to $3 billion. From @leeminjeong83 @shiringhaffary https://t.co/1aPoEbJxCz
🤖🇯🇵 SoftBank's AI Healthcare Marriage with Tempus Is Transforming Medicine! Check out how Son's latest joint venture leverages AI for personalized cancer treatment in Japan. This is huge for healthcare and AI enthusiasts alike! https://t.co/KuZaarAn8a
SoftBank Group’s Vision Fund 2 is investing in U.S. artificial intelligence startup Perplexity AI at a $3 billion valuation. https://t.co/SNi7f9YOY9
